GlassScriptPhysician profile
Melissa Ann Carran
NPI 1346266939
$4,503.34
in general payments reported to CMS, 2019-2025
45 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $193 · 2021: $324 · 2022: $387 · 2023: $632 · 2024: $537 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,463 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,462.88 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.36 | 2021-2025 | Botox, Ubrelvy |
| Sk Life Science, INC. | $613.31 | 2020-2025 | Xcopri |
| Ucb, INC. | $442.45 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Jazz Pharmaceuticals INC. | $187.00 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $166.94 | 2019-2020 | |
| Eisai INC. | $166.84 | 2019-2025 | |
| Neuropace, INC. | $156.62 | 2023 | |
| Neurocrine Biosciences, INC. | $133.52 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $133.44 | 2019-2025 | Austedo Xr, Austedo Xr |
| Livanova USA, INC. | $124.88 | 2019 | |
| Emd Serono, INC. | $123.62 | 2019 | |
| Allergan, INC. | $112.33 | 2019-2020 | |
| Pfizer INC. | $101.06 | 2025 | |
| Neurelis, INC. | $96.83 | 2021-2025 | Valtoco |
| Biogen, INC. | $79.98 | 2019-2025 | Vumerity, Tysabri |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Carran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.